YourChoice Therapeutics commences male birth control pill trial
YourChoice Therapeutics has commenced the dosing of subjects in a Phase I clinical trial of YCT-529 for its potential as…
YourChoice Therapeutics has commenced the dosing of subjects in a Phase I clinical trial of YCT-529 for its potential as…
Dicot has dosed the first participants in a Phase I clinical trial of LIB-01 to treat erectile dysfunction and premature…
Endurance announced that its commercial partner Wanbang Biopharmaceuticals has completed a Phase III study of Fortacin (lidocaine/prilocaine) in China for…
Prostate cancer is the fourth most common cancer worldwide and the most common cancer among men in the UK. In…
Tavanta Therapeutics has concluded subject enrolment in its pivotal Phase III clinical trial of TAVT-45 (abiraterone acetate) granules for oral…
In May 2018, the US Preventive Services Task Force (USPSTF) published new prostate cancer screening guidelines, which had last been…
Within the pharmaceutical sphere, it is commonly known that the development of reversible male contraception has been extremely difficult. Options…
Astellas Pharma and Pfizer have reported that their drug Xtandi (enzalutamide) enhanced overall survival (OS) in the Phase III ARCHES…
Pfizer has dosed the first subject in a Phase III TALAPRO-3 clinical trial of oral drug talazoparib plus enzalutamide in…
Telix Pharmaceuticals has begun a Phase III ProstACT clinical trial of its therapy candidate, TLX591 (177Lu-DOTA-rosopatamab), in advanced metastatic castrate-resistant…